Investing.com — Cel-Sci Corp (NYSE:CVM)股票已跌至52周新低，交易价格为0.26美元，这家生物技术公司正面临市值大幅下降的艰难时期。InvestingPro数据显示，该公司的财务健康评分处于令人担忧的1.39，被标记为"疲弱"，仅在过去一周内股价就下跌了10.7%。在过去一年中，公司股价已下跌了惊人的85.79%，反映了投资者的担忧以及可能存在的更广泛板块逆风 ...

Cel-Sci Corp (CVM)股价触及52周新低，跌至$0.31，这家生物科技公司正经历充满挑战的时期，股价大幅下跌。 InvestingPro 数据显示其财务健康评分较低，仅为1.51，但分析师仍维持$6至$10的目标价，表明尽管当前面临挑战，但仍存在上涨潜力。过去一年，Cel-Sci ...

VetStem, Inc. has secured funding for final development work on StemStatTM Ortho for conditional approval submission to the FDA CVM. This additional funding allows us to finalize the regulatory ...

The U.S. Food and Drug Administration’s Center for Veterinary Medicine has completed an evaluation of adverse events reported in dogs of various ages treated with Librela (bedinvetmab injection).

--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer ... 740 patients and received Orphan Drug designation from the FDA for ...

The U.S. Food and Drug Administration’s Center for Veterinary Medicine has completed an evaluation of adverse events reported in dogs of various ages treated with Librela (bedinvetmab injection).

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Detailed price information for Petvivo Holdings Inc WT (PETVW) from The Globe and Mail including charting and trades.